Level D· Preclinical EvidenceLaboratory Study

Aberrantly expressed long noncoding RNAs in adipose-derived mesenchymal stem cells differentiation to nucleus pulposus-like cells.

Zhu J., Jin L., Jin K., Wu Y., Sun L., Huang Y.

Laboratory Study on Disc Degeneration, published in Sci Rep (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type: Laboratory Study
Journal: Sci Rep (2026)
Country: England
Reported sample size: —
PMID: 41667574
DOI: 10.1038/s41598-026-36219-5

Abstract (original English)

Stem cell-based therapy holds promise for intervertebral disc degeneration (IDD) regeneration, but the underlying mechanisms require further elucidation. Long noncoding RNAs (lncRNAs) have been implicated in physiological processes such as apoptosis and differentiation. While numerous studies have investigated messenger RNAs (mRNAs) and lncRNAs in normal versus degenerated nucleus pulposus (NP), the differential expression of lncRNAs and mRNAs during stem cell differentiation into NP-like cells remains poorly characterized. This study aimed to identify differentially expressed mRNAs and lncRNAs during the differentiation of human adipose-derived mesenchymal stem cells (hADSCs) into NP-like cells and to explore the associated signaling pathways and regulatory networks. hADSCs were induced to differentiate into NP-like cells using a cytokine cocktail. Differentiation was confirmed by assessing marker gene expression via PCR and immunofluorescence staining. RNA sequencing (RNA-seq) was employed to profile lncRNA and mRNA expression during differentiation. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were used to identify the biological functions and pathways associated with the significantly altered genes. 500 lncRNAs (217 up and 283 down) and 601 mRNAs (269 up and 332 down) were significantly differentially expressed during hADSC differen

What this study does not prove

• This study does not prove SVF is an approved treatment or a replacement for standard care.
• This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence

HumansMesenchymal Stem CellsRNA, Long NoncodingCell DifferentiationNucleus PulposusRNA, MessengerAdipose TissueGene Expression ProfilingGene Expression RegulationIntervertebral Disc Degeneration

Back & Spine Hip Disc Degeneration

View on PubMed DOI

Aberrantly expressed long noncoding RNAs in adipose-derived mesenchymal stem cells differentiation to nucleus pulposus-like cells.

Abstract (original English)

What this study does not prove

Evidence level

Related research

Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies.

Stem cells and discogenic back pain.

Potential Role for Stem Cell Regenerative Therapy as a Treatment for Degenerative Disc Disease and Low Back Pain: A Systematic Review.

Mesenchymal Stem Cell Levels of Human Spinal Tissues.

A systematic review of the safety and efficacy of mesenchymal stem cells for disc degeneration: insights and future directions for regenerative therapeutics.

Cell-Free Fat Extract (CEFFE) as a Versatile Cell-Free Biologic for Multitissue Regeneration: From Skin and Bone to Nerve, Reproductive, and Systemic Applications-A Comprehensive Review.